-
Je něco špatně v tomto záznamu ?
Reprogramming of human pancreatic organoid cells into insulin-producing β-like cells by small molecules and in vitro transcribed modified mRNA encoding neurogenin 3 transcription factor
T. Koblas, I. Leontovyc, S. Loukotová, F. Saudek
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2000
Freely Accessible Science Journals
od 2000
ProQuest Central
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
- MeSH
- antigen AC133 metabolismus MeSH
- beta-buňky cytologie účinky léků MeSH
- dospělí MeSH
- genetická transkripce účinky léků MeSH
- inzulin biosyntéza MeSH
- knihovny malých molekul farmakologie MeSH
- lidé MeSH
- messenger RNA genetika metabolismus MeSH
- organoidy cytologie MeSH
- přeprogramování buněk účinky léků genetika MeSH
- proliferace buněk MeSH
- proteiny nervové tkáně genetika metabolismus MeSH
- transkripční faktory bHLH genetika metabolismus MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Reprogramming of non-endocrine pancreatic cells into insulin-producing cells represents a promising therapeutic approach for the restoration of endogenous insulin production in diabetic patients. In this paper, we report that human organoid cells derived from the pancreatic tissue can be reprogrammed into the insulin-producing cells (IPCs) by the combination of in vitro transcribed modified mRNA encoding transcription factor neurogenin 3 and small molecules modulating the epigenetic state and signalling pathways. Upon the reprogramming, IPCs formed 4.6 ± 1.2 % of the total cells and expressed typical markers (insulin, glucokinase, ABCC8, KCNJ11, SLC2A2, SLC30A8) and transcription factors (PDX1, NEUROD1, MAFA, NKX2.2, NKX6.1, PAX4, PAX6) needed for the proper function of pancreatic β-cells. Additionally, we have revealed a positive effect of ALK5 inhibitor RepSox on the overall reprogramming efficiency. However, the reprogrammed IPCs possessed only a partial insulin-secretory capacity, as they were not able to respond to the changes in the extracellular glucose concentration by increasing insulin secretion. Based on the achieved results we conclude that due to the incomplete reprogramming, the IPCs have immature character and only partial properties of native human β-cells.
1st Faculty of Medicine Charles University Prague Czech Republic
Department of Diabetes Institute for Clinical and Experimental Medicine Prague Czech Republic
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005455
- 003
- CZ-PrNML
- 005
- 20200608143400.0
- 007
- ta
- 008
- 200511s2019 xr d f 000 0|eng||
- 009
- AR
- 024 __
- $a 10.14712/fb2019065030109 $2 doi
- 035 __
- $a (PubMed)31638558
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Koblas, Tomáš $7 xx0070806 $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 10
- $a Reprogramming of human pancreatic organoid cells into insulin-producing β-like cells by small molecules and in vitro transcribed modified mRNA encoding neurogenin 3 transcription factor / $c T. Koblas, I. Leontovyc, S. Loukotová, F. Saudek
- 504 __
- $a Literatura
- 520 9_
- $a Reprogramming of non-endocrine pancreatic cells into insulin-producing cells represents a promising therapeutic approach for the restoration of endogenous insulin production in diabetic patients. In this paper, we report that human organoid cells derived from the pancreatic tissue can be reprogrammed into the insulin-producing cells (IPCs) by the combination of in vitro transcribed modified mRNA encoding transcription factor neurogenin 3 and small molecules modulating the epigenetic state and signalling pathways. Upon the reprogramming, IPCs formed 4.6 ± 1.2 % of the total cells and expressed typical markers (insulin, glucokinase, ABCC8, KCNJ11, SLC2A2, SLC30A8) and transcription factors (PDX1, NEUROD1, MAFA, NKX2.2, NKX6.1, PAX4, PAX6) needed for the proper function of pancreatic β-cells. Additionally, we have revealed a positive effect of ALK5 inhibitor RepSox on the overall reprogramming efficiency. However, the reprogrammed IPCs possessed only a partial insulin-secretory capacity, as they were not able to respond to the changes in the extracellular glucose concentration by increasing insulin secretion. Based on the achieved results we conclude that due to the incomplete reprogramming, the IPCs have immature character and only partial properties of native human β-cells.
- 650 _2
- $a antigen AC133 $x metabolismus $7 D000071916
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a transkripční faktory bHLH $x genetika $x metabolismus $7 D051792
- 650 _2
- $a proliferace buněk $7 D049109
- 650 _2
- $a přeprogramování buněk $x účinky léků $x genetika $7 D065150
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inzulin $x biosyntéza $7 D007328
- 650 _2
- $a beta-buňky $x cytologie $x účinky léků $7 D050417
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a proteiny nervové tkáně $x genetika $x metabolismus $7 D009419
- 650 _2
- $a organoidy $x cytologie $7 D009940
- 650 _2
- $a messenger RNA $x genetika $x metabolismus $7 D012333
- 650 _2
- $a knihovny malých molekul $x farmakologie $7 D054852
- 650 _2
- $a genetická transkripce $x účinky léků $7 D014158
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Leontovyč, Ivan. $7 xx0239101 $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Loukotová, Šárka. $7 xx0248561 $u First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Saudek, František, $d 1955- $7 nlk20000083698 $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 773 0_
- $w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 65, č. 3 (2019), s. 109-123
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31638558 $y Pubmed
- 856 41
- $u https://fb.cuni.cz/file/5896/fb2019a0011.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 970 $c 89 $y p $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200602164450 $b ABA008
- 999 __
- $a ok $b bmc $g 1532564 $s 1095510
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 65 $c 3 $d 109-123 $i 0015-5500 $m Folia biologica (Praha) $n Folia biol. (Praha) $x MED00011004
- LZP __
- $b NLK118 $a Pubmed-20200511